New England Journal of Medicine paper released today - what started as the first in vivo clinical trial for CRISPR gene editing, for CEP290-associated retinal degeneration. Congrats to all. @MassEyeandEar@harvardmed@HMSeye@CaseyEye@editasmed#ARVO2024 https://t.co/lSH8jo3tyj
Congratulations Kannan and team! I’m very proud of you and the data looks amazing. We discovered over 800 mutations in rhodopsin - triple the number in ClinVar from all prior submissions. Special thanks too to the @OctantBio team for advancing RHO research.
Presenting our work on "Deep mutational scanning reveals the pathogenicity and structural insights into rhodopsin missense variants" was a true privilege. Huge thanks to Octant Bio and Dr.Jason Comander, whose guidance was instrumental to this project.#ARVO2024
The vision of 22-year-old Olivia Cook has improved, and so has her hope for the future thanks to an experimental gene-editing treatment called #CRISPR. Learn more about the groundbreaking study from lead investigator Eric Pierce, MD, PhD: https://t.co/VVZJWMDPOQ via @CNN.
New England Journal of Medicine paper released today - what started as the first in vivo clinical trial for CRISPR gene editing, for CEP290-associated retinal degeneration. Congrats to all. @MassEyeandEar@harvardmed@HMSeye@CaseyEye@editasmed#ARVO2024 https://t.co/lSH8jo3tyj
Faculty member @JasonComander will be discussing the latest Stargardt’s research and the biological basis of the disease at the virtual Stargardt’s Summit next Wednesday, February 29.
@FightBlindness Thanks so much Ben for having me on the show! Glad to give an update on vitamins and RP. I’m not used to talking about myself so much but hope people enjoyed the stories and info!
Are you ready for our final Eye on the Cure episode of 2023? In this week's episode, host Ben Shaberman chats with Jason Comander, Md, PhD.
Learn more about streaming at: https://t.co/JtOlHLgZbB
Usher syndrome is a hereditary condition responsible for nearly half of all deaf-blindness cases. Today, on #USHDAY, Mass Eye and Ear researchers Zheng-Yi Chen, DPhil, and Qin Liu, MD, PhD lend their expertise on the disease: https://t.co/CpL4UF0wm0
@RetinaToday There is no room on twitter for a sophisticated rebuttal, but suffice to say that many specialists in the inherited retinal disease field would strongly disagree. It’s just not true- gene therapy will continue to help our patients.
@MoodCritic @JohnDoench If you want low MOI, we noticed that "dialing down" lentivirus to 1 copy per cell works much better than for AAV. I think, because 1 copy of successfully-transduced lentivirus gives higher detectable expression than one copy of active AAV. Depends on the cell type though.
Today I saw a patient that is seeing the other Dr. Comander- that would be my amazing husband, retina specialist & physician scientist @JasonComander, in just a few weeks…… I think this is the first time we have shared a patient!